ClinicalTrials.gg
RecruitingNCT04993131TESLA IIUpdated Oct 16, 2026

Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma

An interventional study of Liver transplant in Perihilar Cholangiocarcinoma, Klatskin Tumor and Bile Duct Cancer, sponsored by Oslo University Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The study will investigate whether liver transplantation provides increased survival, low side effects and good quality of life in patients with bile duct cancer where the tumor cannot be removed by normal surgery. Analyzes of blood and tissue samples from the tumor will be investigated to see if the analyzes can indicate who may have recurrence of the disease after liver transplantation. Furthermore, the effect of chemotherapy on normal liver and tumor tissues in the liver that are removed during transplantation will be investigated.

Read the detailed description

Liver transplantation (Lt) is an established method of treatment for acute and chronic liver failure. One and five- year survival after Lt is approximately 90% and 80%, respectively. Currently, Lt is a treatment option for selected patients with primary carcinomas in the liver and in patients with liver metastases from neuroendocrine tumors. The prerequisite is that there is no extra-hepatic tumor growth and that the primary tumor is removed. Lt for cancer comprises of 14% of all Lts in Europe (www.etlr.org). Types of primary carcinomas eligible for transplantation today include hepatocellular carcinoma (HCC), hepatoblastoma, hemangioendothelioma, and perihilar cholangiocarcinoma (pCCA), the latter in clinical protocols. The most common secondary hepatocarcinomas are neuroendocrine tumours (carcinoid tumours and gastrinomas). The International Registry of Hepatic Tumors in Liver Transplantation show that survival of HCC patients after transplantation is above 70% and 60% at 1 and 5 years, respectively. Recent studies on HCC and liver transplantation have shown even better results when patients are treated with an immunosuppressive regimen containing the antiproliferative agent rapamycin. For hepatoblastoma (children) and malign hemangioendotheliaoma the five-year survival is between 50-60% and for intestinal sarcomas and neuroendocrine tumours it is approximately 35-40%. In patients transplanted for pCCA using a multimodal approach utilizing neoadjuvant radiation, chemotherapy and liver transplantation (Mayo protocol) 5-year patient survival of >80% in selected patients compared to a corresponding 21% five-year survival in liver resection.

Malignancy of the biliary tree (cholangiocarcinoma, CCA) is a rare cancer with an annual incidence around 150 cases in Norway. Cholangiocarcinoma can be subdivided into distal, perihilar, and intrahepatic according to their anatomical location5. Although rare, intrahepatic cholangiocarcinoma (iCCA) constitutes the second most common primary liver cancer after hepatocellular carcinoma, and the worldwide incidence of iCCA is increasing. Despite improvements in multidisciplinary management, patients with CCA have a poor outcome and only 20% of patients are eligible for surgical resection, with 5-year overall survival of less than 10% for all patients. The only potentially curative treatment option is surgical resection with complete excision of tumor with negative margins.

An Irish study with liver transplantation for patients with unresectable hilar CCA who received neoadjuvant chemoradiotherapy had 1- , 3- and 5-year survival of 81%, 69% and 62% respectively, of the transplanted patients. We have recently started a prospective exploratory study, TESLA trial, investigating Lt in non-resectable iCCA with stable disease on oncological treatment.

Building on these results in addition to our own experience with liver transplantation for non-resectable colorectal liver metastases, we want to investigate in the TESLA-II trial the role of Lt in selected patients with unresectable pCCA, who fulfill the inclusion criteria.

02

Conditions studied

  • Perihilar Cholangiocarcinoma
  • Klatskin Tumor
  • Bile Duct Cancer
03

In context

Klatskin Tumor

82 studies on the registry are indexed under Klatskin Tumor; 27 are open to participants now.

This study's planned enrollment of 15 is below the median of 55 across 56 interventional studies indexed under Klatskin Tumor.

Browse Klatskin Tumor studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radiologically strong suspicion of pCCA
  • Tumor can involve intrahepatic portal vein without thrombosis of extrahepatic portal vein
  • Tumor can involve hepatic artery distal to gastroduodenal artery or involve replaced hepatic artery
  • First time pCCA
  • Disease deemed not eligible for liver resection based on tumor location or underlying liver dysfunction
  • No extrahepatic disease, or lymph node involvement detected on imaging
  • No signs of extrahepatic disease according to PET-CT scan
  • No signs of extrahepatic metastatic disease according to CT or MR (chest/abdomen/pelvis) scan within 4 weeks prior to the faculty meeting at the transplant unit
  • At least 18 years of age
  • Good performance status, (ECOG) score: 0 or 1
  • Satisfactory blood tests >10g/dl, neutrophiles >1.0 (after any G-CSF), TRC >50, \<3 x upper normal level, ASAT, ALAT\<5 x upper normal level, Creatinine \<1.5 x upper normal level. Albumin above lower normal level, Normal IgG4 levels
  • Signed and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to GCP, and national/local regulations
  • Received chemotherapy for at least 6 months with at least 10% response according ti criteria and with no progression of disease at time of Lt
  • At least 10 months from diagnosis
  • Patient must be accepted for transplantation before progressive disease
  • Twelve months or more time span from the diagnosis of pCCA and date of being listed for liver transplantation

Exclusion criteria

Exclusion criteria

  • Tumor involving common hepatic artery, celiac trunck or superior mesenteric artery the tumor
  • Tumor involving main portal vein
  • Tumor involving inferior vena cava
  • Perforation of the visceral peritoneum
  • Weight loss >15% the last 6 months
  • Patient > 30
  • Other , except curatively treated more than 5 years ago without relapse
  • Known history of (HIV) infection
  • Prior history of solid organ or bone marrow transplantation
  • Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • Known to rapamycin
  • Prior extrahepatic disease
  • Women who are pregnant or breast feeding
  • Any reason why, in the opinion of the investigator, the patient should not participate
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Liver transplant

    The patients will be transplanted according to standard procedures by the institutional protocol. Median time of surgery is 7 hours and 20 minutes. Each surgical procedure will be performed by specialists at the Rikshospitalet liver transplantation team, which consists of seven specialists at the unit. The transplantation procedure is initiated by an exploratory laparotomy with clinical assessment and frozen section of the lymphnodes in the hepatoduodenal ligament and along the common hepatic artery/coeliac axis. Complete clearance of the lymphatic tissue around the hepatoduodenal ligament. Frozen section is obtained from the distal end of the common bile duct. Evidence of disease dissemination to these regional lymph nodes will be an absolute contraindication to transplantation.

    Procedure: Liver transplant

Interventions

  • ProcedureLiver transplant

    Liver transplant.

06

What researchers measure

Primary outcomes

  1. Overall survival

    Patient record

    Time frame: From screening and until 36 months after inclusion

Secondary outcomes

  1. Overall survival from time of relapse

    Patient record

    Time frame: From time of relapse and until 36 months after inclusion

  2. Disease free survival

    CT-scan/MRI scan according to RECISTcriteria

    Time frame: After liver transplantation and up 10 years after liver transplantation

  3. Time to start of new treatment/change in strategy

    Patient record

    Time frame: Immediately after liver transplatation to start of new treatment

  4. Quality of life (EORTC QLQ-C30), time to decrease in physical function and global health score

    Quality of life measured by EORTC QLQ-C30

    Time frame: Up to 10 years after liver transplantation

  5. Complication according to Clavien-Dindo grad 3-5

    Patient record

    Time frame: Up to 90 days after liver transplantation

  6. Diagnosis of other malignancies

    Patient record

    Time frame: Up to 10 years after liver transplantation

  7. Survival in relation to biological markers

    CA19-9, CEA

    Time frame: After Liver Transplant until 10 years after liver transplantation

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2021 (actual). Primary completion is estimated for May 2035, 164 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2021
First posted
Aug 6, 2021
StartActual
Sep 1, 2021
Primary completionEst.
May 31, 2035
CompletionEst.
May 31, 2045
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and oversight details
1 update, last Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Minor edits only
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04993131
Responsible party
Sheraz Yaqub (Assoc Professor, MD PhD FEBS, Oslo University Hospital) — Principal investigator
First posted
Aug 6, 2021
Start date
Sep 1, 2021
Primary completion
May 31, 2035 (estimated)
Completion
May 31, 2045 (estimated)
Last update
Oct 16, 2026

Study contacts

Sheraz Yaqub, MD PhD
Contact
shya@ous-hf.no
+4723073296
Pål-Dag Line, MD PhD
Contact
pline@ous-hf.no
+4723070509

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion